BAT5906 vs Tarcocimab tedromer

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Age-Related Macular Degeneration

Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline

BAT5906

Developed by Bio-Thera Solutions

Phase 3 in Age-Related Macular Degenerationmonoclonal antibody
Partial signal

NCT05439629 · Phase 3 · completed

The study randomized 488 participants to BAT5906 or active treatment with Lucentis and masked participants, care providers, and investigators. Its primary outcomes were clinical measures of visual acuity, but the registry does not report whether the comparison was favorable or statistically significant, so the evidence remains limited pending results.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

No aligned efficacy figure on record for this race.

Tarcocimab tedromer

Developed by Kodiak Sciences Inc.

Phase 3 in Age-Related Macular Degenerationmonoclonal antibody-biopolymer conjugate
Partial signal

NCT06556368 · Phase 3 · active, not recruiting

This was a randomized, quadruple-masked Phase 3 trial with 675 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-09-28. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.

Reported efficacy

Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to the Average of Non-missing BCVA Values of Weeks 40, 44 and 48. (Day 1 to Week 48): Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to the Average of Non-missing BCVA Values of Weeks 40, 44 and 48. (Day 1 to Week 48): KSI-301 (Treatment Group A) 2.5 ETDRS Letters (Standard Error 0.78) vs Aflibercept (Treatment Group B) 4.6 ETDRS Letters (Standard Error 0.76) (met)

Result source: NCT04964089

Results for Age-Related Macular Degeneration

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

BAT5906: no structured comparison results are available for Age-Related Macular Degeneration.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Tarcocimab tedromer

BCVA Change Letters 2.5 vs 4.6 Aflibercept ETDRS Letters @ 44wk
absolute change · ETDRS Letters
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Gain 5 Letters 36.2% (n=276) vs 34.2% (n=281) Aflibercept @ 2wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 2
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 100 Participants as posted
BCVA Gain 5 Letters 39.9% (n=276) vs 45.9% (n=281) Aflibercept @ 4wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 4
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 110 Participants as posted
BCVA Gain 5 Letters 43.1% (n=276) vs 53.7% (n=281) Aflibercept @ 8wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 8
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 119 Participants as posted
BCVA Gain 5 Letters 44.9% (n=276) vs 52.7% (n=281) Aflibercept @ 12wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 12
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 124 Participants as posted
BCVA Gain 5 Letters 43.1% (n=276) vs 50.9% (n=281) Aflibercept @ 16wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 16
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 119 Participants as posted
BCVA Gain 5 Letters 43.8% (n=276) vs 57.3% (n=281) Aflibercept @ 20wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 20
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 121 Participants as posted
BCVA Gain 5 Letters 47.1% (n=276) vs 55.5% (n=281) Aflibercept @ 24wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 24
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 130 Participants as posted
BCVA Gain 5 Letters 44.2% (n=276) vs 54.8% (n=281) Aflibercept @ 28wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 28
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 122 Participants as posted
BCVA Gain 5 Letters 47.8% (n=276) vs 59.8% (n=281) Aflibercept @ 32wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 32
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 132 Participants as posted
BCVA Gain 5 Letters 43.5% (n=276) vs 56.2% (n=281) Aflibercept @ 36wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 36
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 120 Participants as posted
BCVA Gain 5 Letters 42% (n=276) vs 55.5% (n=281) Aflibercept @ 40wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 40
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 116 Participants as posted

+ 68 further endpoints in the CSV export.

Available safety results

Tarcocimab tedromer

Dropout rate
8.3%
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
Discontinued due to AEs
2.9%
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
Serious AEs
14.1%
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
Most frequent reported AEs
covid-19 12.3%
neovascular age-related macular degeneration - fellow eye 8%
vitreous floaters - study eye 7.6%
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BAT5906's landscape · Tarcocimab tedromer's landscape